BECTON DICKINSON IMMUNOCYTOMETRY SYSTEMS SALES WILL NEAR $200 MIL. IN FY 1996, FIRM SAYS; UNIT POSTS "DOUBLE-DIGIT" REVENUE GAINS IN SECOND QUARTER
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson's flow cytometry business is operating at an approximately $200 mil.-a-year revenue rate, Deborah Neff, president of BD Immunocytometry Systems, told analysts April 25 in New York City. Driven by new product introductions, the division posted a double-digit percentage increase in sales during the company's second fiscal quarter (ended March 31).